Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Eoganachton Mar 22, 2024 4:31pm
179 Views
Post# 35948069

RE:RE:RE:Additions to Study Design

RE:RE:RE:Additions to Study DesignOnce Ruvidar PDT is approved Theralase will be able to point to it's superior efficacy immediately and it's superior durable response will emerge more and more over time as Ruvidar maintains it's CR rate while Adstliladrin (for example) declines. With safety and only one or two treatments required Ruvidar will become the obvious choice.

Eoganacht wrote: I think this is good. The trial still ends at 450 days past initial response, but Theralase will continue to compile durable response data. I don't think any prospective treatment we've heard about so far will be able to compete with Ruvidar PDT's durable response and Theralase will have the data to prove it.

Oilminerdeluxe wrote: Ungodly frustrating. But what can you do? Hope we get a nice update whenever it arrives.




<< Previous
Bullboard Posts
Next >>